115 related articles for article (PubMed ID: 12692521)
1. Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).
Rechner I; Brito-Babapulle F; Fielden J
Hematol J; 2003; 4(1):54-6. PubMed ID: 12692521
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
3. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents.
Lerro KA; Medoff E; Wu Y; Seropian SE; Snyder E; Krause D; Cooper DL
Bone Marrow Transplant; 2003 Dec; 32(12):1113-7. PubMed ID: 14647264
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte colony-stimulating factor-induced capillary leak syndrome confirmed by extravascular lung water measurements.
Deeren DH; Zachee P; Malbrain ML
Ann Hematol; 2005 Feb; 84(2):89-94. PubMed ID: 15365768
[TBL] [Abstract][Full Text] [Related]
5. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR
Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306
[TBL] [Abstract][Full Text] [Related]
7. Adverse side-effects associated with G-CSF in patients with chronic myeloid leukemia undergoing allogeneic peripheral blood stem cell transplantation.
Khoury H; Adkins D; Brown R; Vij R; Westervelt P; Trinkaus K; Goodnough LT; DiPersio JF
Bone Marrow Transplant; 2000 Jun; 25(11):1197-201. PubMed ID: 10849533
[TBL] [Abstract][Full Text] [Related]
8. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.
Paripati H; Stewart AK; Cabou S; Dueck A; Zepeda VJ; Pirooz N; Ehlenbeck C; Reeder C; Slack J; Leis JF; Boesiger J; Torloni AS; Fonseca R; Bergsagel PL
Leukemia; 2008 Jun; 22(6):1282-4. PubMed ID: 18216870
[No Abstract] [Full Text] [Related]
9. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma.
Maiolino A; Hungria VT; Garnica M; Oliveira-Duarte G; Oliveira LC; Mercante DR; Miranda EC; Quero AA; Peres AL; Barros JC; Tanaka P; Magalhães RP; Rego EM; Lorand-Metze I; Lima CS; Renault IZ; Braggio E; Chiattone C; Nucci M; de Souza CA;
Am J Hematol; 2012 Oct; 87(10):948-52. PubMed ID: 22730113
[TBL] [Abstract][Full Text] [Related]
10. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients.
Mazumder A; Kaufman J; Niesvizky R; Lonial S; Vesole D; Jagannath S
Leukemia; 2008 Jun; 22(6):1280-1; author reply 1281-2. PubMed ID: 18033320
[No Abstract] [Full Text] [Related]
11. [Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia].
Boqué C; Grañena A
Sangre (Barc); 1998 Apr; 43(2):155-63. PubMed ID: 9656777
[No Abstract] [Full Text] [Related]
12. Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.
Galli M; Nicolucci A; Valentini M; Belfiglio M; Delaini F; Crippa C; Barbui AM; Giussani U; Rambaldi A; Barbui T
Haematologica; 2005 Dec; 90(12):1643-9. PubMed ID: 16330437
[TBL] [Abstract][Full Text] [Related]
13. Blood stem cell collection using chemotherapy with or without systematic G-CSF: experience in 52 patients with multiple myeloma.
Lefrere F; Makke J; Fermand J; Marolleau J; Dal Cortivo L; Alberti C; Mouton V; Benbunan M; Miclea J
Bone Marrow Transplant; 1999 Sep; 24(5):463-6. PubMed ID: 10482928
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma.
Bilgrami S; Bona RD; Edwards RL; Li Z; Naqvi B; Shaikh A; Furlong F; Fox J; Clive J; Tutschka PJ
Bone Marrow Transplant; 2001 Jul; 28(2):137-43. PubMed ID: 11509931
[TBL] [Abstract][Full Text] [Related]
15. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
[TBL] [Abstract][Full Text] [Related]
16. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.
Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Gastineau DA; Litzow MR; Fonseca R; Roy V; Rajkumar SV; Gertz MA
Leukemia; 2007 Sep; 21(9):2035-42. PubMed ID: 17581613
[TBL] [Abstract][Full Text] [Related]
17. [Two cases of malignant lymphoma with high fever and C-reactive protein (CRP) elevation after treatment with granulocyte colony-stimulating factor (G-CSF)].
Kanbayashi Y; Mukoyama N; Nishida K; Shimizu D; Matsumoto Y; Nomura K; Horiike S; Taniwaki M
Gan To Kagaku Ryoho; 2006 Jan; 33(1):73-7. PubMed ID: 16410701
[TBL] [Abstract][Full Text] [Related]
18. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
19. Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy.
Takemoto Y; Wada H; Takatsuka H; Okamoto T; Kakishita E
Drugs Exp Clin Res; 2000; 26(1):1-5. PubMed ID: 10761530
[TBL] [Abstract][Full Text] [Related]
20. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.
Hovenga S; de Wolf JT; Guikema JE; Klip H; Smit JW; Smit Sibinga CT; Bos NA; Vellenga E
Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
